ArticleJournal of molecular modeling2026
Molecular docking, Group Interaction Contribution (GIC), and ADMET studies on the role of surfactants in improving the permeability and solubility of mitoxantrone.
Article in Journal of molecular modeling, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
contextMitoxantrone (MTX) is an anticancer drug characterized by its hydrophobicity and low bioavailability, which can be increased by adding adjuvants to the formulation, such as surfactants (SFT). They can interact effectively with drugs, improve solubility and permeability, and stabilize them, thanks to unique properties such as amphiphilicity, adsorption, and micellization.
methodsThis novel in silico study explores the intermolecular interactions between 128 surfactants and the chemotherapeutic anticancer agent "Mitoxantrone", using molecular docking and the GIC approach. First, the MTX-SFT complexes were generated through ligand-ligand docking, showing various interactions (e.g., H-bond, π-π stacking, Pi-Alkyl). Next, to evaluate the effectiveness of these structural combinations in inhibiting Topoisomerase IIα (PDB ID: 1ZXM), a series of docking studies was performed to assess a variety of binding poses and ultimately determine the top-scoring complexes and the best binding poses.
resultsThe docking results revealed that, among the 128 complexes generated, 70 complexes exhibited good Binding Energy (∆G) ranging from -34,727 to -48.116 kJ/mol. The ADMET evaluation was performed on the complexes with the highest affinity, identifying the top 33 complexes with favorable pharmacokinetic properties. Among the MTX-SFT complexes - that have top-scoring and exhibited greater inhibitory activity against topoisomerase IIα than other modified forms are MTX-Sodium Ricinoleate, MTX-Magnesium Ricinoleate, MTX-Glyceryl Laurate (Monolaurin), MTX-Sodium Lauroyl Sarcosinate, MTX-Sphingosine-1-Phosphate, MTX-Glyceryl Caprate, and MTX-Sorbitan Monolaurate (Span20). Additionally, the (GIC) approach demonstrated a strong relationship between molecular structure and interaction efficiency. The linear model yielded an AARD% of 1,4247% (R
conclusionsThis study emphasizes the potential of surfactants to improve the properties of Mitoxantrone and enhance its therapeutic efficacy against breast cancer, paving the way for the development of more effective and safer anticancer therapies.
Indexed as
Identifiers
42616176What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.